NCT04506554 2025-07-04
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer
Fox Chase Cancer Center
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT04724928 2025-01-15
EFFORT-MIBC
University Hospital, Ghent
Phase 2 Recruiting
NCT05203913 2024-10-04
CNN-BC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Recruiting
NCT04876313 2022-04-06
NURE-Combo
IRCCS San Raffaele
Phase 2 Unknown
NCT04909775 2021-06-02
Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer
Ruijin Hospital
Phase 2 Unknown